Anika Therapeutics, Inc. Enters into Third Amendment to Credit Agreement Amending its Existing Revolving Line of Credit Agreement
November 15, 2021 at 07:58 am EST
Share
On November 12, 2021, Anika Therapeutics, Inc. entered into a Third Amendment to Credit Agreement amending its existing revolving line of credit agreement dated October 24, 2017 with Bank of America, N.A., which revolving line of credit agreement, as amended to date (including by such Third Amendment). Under the amended agreement, Bank of America, N.A. serves as administrative agent, issuer of letters of credit and swingline lender for a $75.0 million senior revolving line of credit with a maturity date of November 12, 2026. Subject to certain conditions, its may request up to an additional $75.0 million in commitments for a maximum aggregate commitment of $150.0 million, subject to the approval of the Revolving Lenders referred to in the Amended Agreement. Loans under the Amended Agreement generally will bear interest at a rate equal to (a) the Bloomberg Short-Term Bank Yield Index, or BSBY, rate plus (b) an additional percentage that will range from 0.25% to 1.00%, based on its consolidated leverage ratio at the time of the borrowings.
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.